Thriving biotech: three stocks building momentum
In this article, Dmytro Spilka explores three promising biotechs that have seen growth in the last year and why they may continue to garner interest.
List view / Grid view
In this article, Dmytro Spilka explores three promising biotechs that have seen growth in the last year and why they may continue to garner interest.
15 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Foetal haemoglobin lacks beta sub-units and has gamma sub-units instead. Thus, beta-thalassemia or SCD–associated mutations, which impair the production or function of the beta sub-unit, do not cause problems with foetal haemoglobin, which can transport oxygen effectively in adults...
21 December 2015 | By Victoria White
Bayer and CRISPR Therapeutics are to form the joint venture to discover, develop and commercialise new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease...
26 October 2015 | By Victoria White
The collaboration will evaluate the use of CRISPR-Cas9 across multiple diseases, including cystic fibrosis, where targets have been validated through human genetics...